Schedule 13G ownership disclosure
Tenax Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 88032L605
Event date: 2024-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vestal Point Capital, LP
Shares: 2,470,096.00 · Class: 9.9%
- Ryan Wilder
Shares: 2,470,096.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-005003
- Form type
- SCHEDULE 13G
- Filer
- TENAX THERAPEUTICS, INC.
- CIK
- CIK 34956
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2024
- Description
- Schedule 13G beneficial ownership